ZXDC

ZXDC is a multi-zinc-finger transcriptional co-activator that drives MHC class I and class II gene expression by partnering with the master regulator CIITA (PMID:16600381). It was identified as a CIITA-binding protein that contacts the leucine-rich repeat region of CIITA, and its overexpression super-activates MHC promoters while its knockdown blunts CIITA-mediated MHC II transcription (PMID:16600381). ZXDC functions not alone but as part of a complex: it self-associates and heterodimerizes with ZXDA through their zinc-finger regions, and it is the ZXDA-ZXDC complex that engages CIITA and occupies MHC II promoters before and after IFN-γ stimulation (PMID:17493635). The activity of its transcriptional activation domain is tuned by SUMO modification at a single lysine, a modification required for full activation-domain function without disrupting its binding to ZXDA or CIITA (PMID:17696781). A truncated, alternatively spliced isoform (ZXDC2) acts as a dominant-negative repressor of IFN-γ-induced MHC II transcription by sequestering ZXDA and full-length ZXDC (PMID:19777325). Beyond immune gene regulation, ZXDC promotes cervical cancer cell metastasis by activating IGF2BP3-dependent stabilization of RhoA mRNA and downstream RhoA/ROCK signaling to remodel the cytoskeleton (PMID:37599824).

1. 2006 High

   Established ZXDC as a physical and functional partner of CIITA, defining a previously unknown co-activator of MHC gene transcription.

   Evidence Yeast two-hybrid screen plus Co-IP and overexpression/siRNA reporter assays in human cells

   PMID:16600381

   Open questions at the time

   • Did not resolve which zinc fingers mediate CIITA binding versus DNA contact
   • No structural model of the ZXDC-CIITA interface
2. 2007 High

   Showed that ZXDC operates as a heterodimer with ZXDA at MHC II promoters, redefining the functional unit of activation as the ZXDA-ZXDC complex rather than ZXDC alone.

   Evidence Reciprocal Co-IP, knockdown/overexpression reporter assays, and ChIP for promoter occupancy in HeLa cells

   PMID:17493635

   Open questions at the time

   • Stoichiometry of the ZXDA-ZXDC-CIITA assembly not defined
   • Whether ZXDC contacts promoter DNA directly is unresolved
3. 2007 High

   Defined SUMO modification at a single lysine as a positive regulator of the ZXDC activation domain, linking post-translational modification to co-activator output.

   Evidence Site-directed mutagenesis, Co-IP with SUMO isoforms and E3 ligases (PIASy), and transcriptional reporter assays

   PMID:17696781

   Open questions at the time

   • Mechanism by which sumoylation enhances activation-domain activity not established
   • Physiological signals controlling ZXDC sumoylation unknown
4. 2009 Medium

   Identified an alternatively spliced isoform (ZXDC2) that acts as a dominant-negative repressor, revealing autoregulation of the MHC II activation program.

   Evidence Isoform cloning, overexpression with IFN-γ and MHC II reporter assays, and Co-IP in HeLa cells

   PMID:19777325

   Open questions at the time

   • Dominant-negative mechanism inferred from overexpression rather than endogenous isoform manipulation
   • Regulation and abundance of endogenous ZXDC2 not characterized
5. 2023 Medium

   Extended ZXDC function beyond immune transcription to cancer metastasis via an IGF2BP3/RhoA/ROCK cytoskeletal axis.

   Evidence Gain- and loss-of-function in cervical cancer cells with migration/invasion assays, in vivo metastasis models, and IGF2BP3/RhoA mRNA-stability readouts

   PMID:37599824

   Open questions at the time

   • Whether ZXDC acts transcriptionally on IGF2BP3 or through another mechanism not fully defined
   • Relationship between the MHC co-activator role and the pro-metastatic role unclear
   • Single cancer-type validation

• How ZXDC integrates its CIITA co-activator role with cell-cycle- or context-dependent functions, and the direct DNA-binding role of its zinc fingers, remain open.
• No direct DNA-binding target sequence defined for the zinc fingers
• No structural characterization of any ZXDC complex
• Mechanistic link between immune and metastatic functions unresolved